|
Total Sample
(n = 66)
Mean ± SD or %, (n)
|
No Atrial Fibrillation
(n = 44)
Mean ± SD or %, (n)
|
Atrial Fibrillation
(n = 22)
Mean ± SD or %, (n)
|
Age* |
68.1 ± 11.5 (66) |
65.1 ± 11.1 (44) |
74.1 ± 9.9
(22) |
Ibrutinib Dose* |
428.5 ± 103.8 (66) |
448.6 ± 88.4 (44) |
388.2 ± 121.7 (22) |
BMI |
27.5 ± 5.8 (66) |
28.1 ± 6.3 (44) |
26.2 ± 4.6
(22) |
Sex, % (n) |
|
|
|
Male |
65.2 (43) |
61.4 (27) |
72.7 (16) |
Female |
34.8 (23) |
38.6 (17) |
27.3 (6) |
Race/Ethnicity, % (n) |
|
|
|
Non-Hispanic White |
74.2 (49) |
77.3 (34) |
68.2 (15) |
Non-Hispanic Black |
7.6 (5) |
6.8 (3) |
9.1 (2) |
Other/Unknown |
18.2 (12) |
15.9 (7) |
22.7 (5) |
Comorbidities, % (n) |
|
|
|
HTN |
77.3 (51) |
79.5 (35) |
72.7 (16) |
HLD |
65.2 (43) |
61.4 (27) |
72.7 (16) |
DM |
28.8 (19) |
13.6 (6) |
59.1 (13) |
CAD |
19.7 (13) |
15.9 (7) |
27.3 (6) |
HF |
16.7 (10) |
9.1 (4) |
27.3 (6) |
MR |
1.5 (1) |
0.0 (0) |
1.5 (1) |
AS |
1.5 (1) |
0.0 (0) |
1.5 (1) |
Malignancy, % (n) |
|
|
|
CLL/SLL |
53.0 (35) |
(22) |
(13) |
Other Lymphoma |
28.8 (19) |
(14) |
(5) |
Plasma Cell Dyscrasia |
16.7 (11) |
(8) |
(3) |
Other |
1.5 (1) |
(0) |
(1) |